Shots:

• Fujifilm acquires Biogen’s subsidiary having the production capacity of 90-000L biologics- in all-stock transaction for $890M. The acquisition is expected to be complete in H2’19
• The focus of an acquisition is to expand Fujifilm’s bio CDMO business. It will provide Biogen a tax relaxation. As a part of the transaction Biogen also signs a service agreement with Fujifilm to develop products for Biogen including Tysabri
• Biogen to develop a new manufacturing facility in Solothurn- Switzerland by H2’20 after the closing of this transaction

Ref: Biogen | Image:Biogen